| abstract |
The invention relates to a pharmaceutical composition for contraception containing, in a daily dose, 2.0 mg or 1.5 mg of 17a-cyanomethyl-17-ß-hydroxyestra-4,9-diene-3on (dienogest) and 0.015 mg of 17a-ethinylestradiol (ethinylestradiol) and (6S)-5-methyltetrahydrofolate, preferably as calcium salt of the (6S)-5-methyltetrahydrofolic acid (metafolin) together with one or more pharmaceutically acceptable auxiliary agents/carriers. The inventive pharmaceutical composition is an oral contraceptive as well as an agent for reducing the risk of congenital malformations. The invention also relates to a kit comprising 21 daily dose units of the pharmaceutical composition and 7 daily dose units containing only (6S)-5-methyltetrahydrofolate, preferably also metafolin. |